产品
编 号：F083922
分子式：C16H18N3S.Cl.xH2O
分子式：C16H18N3S.Cl.xH2O
产品类型
规格
价格
是否有货
1g
168
In-stock
5g
280
In-stock
结构图
CAS No: 122965-43-9
产品详情
生物活性：
Methylene blue (Basic Blue 9) hydrate is a guanylyl cyclase (sGC), monoamine oxidase A (MAO-A) and NO synthase (NOS) inhibitor. Methylene blue is a vasopressor and is often used as a dye in several medical procedures. Methylene blue hydrate through the nitric oxide syntase/guanylate cyclase signalling pathway to reduce prepulse inhibition. Methylene blue hydrate is a REDOX cycling compound and able to cross the blood-brain barrier. Methylene blue hydrate is a Tau aggregation inhibitor. Methylene blue hydrate reduces cerebral edema, attenuated microglial activation and reduced neuroinflammation.
体内研究：
Methylene blue (Basic Blue 9) hydrate (50 and 100 mg/kg; i.p.; once, for 25 min; male NMRI mice) reduces absent prepulse inhibition.Methylene blue hydrate (20 and 40 mg/kg; p.o.; daily, for 6 months; CaMKIIα-tTA transactivator mice) preserves cognition in mice expressing full-length pro-aggregant human Tau.Methylene blue hydrate (2 mg/kg; i.v.; once, for 1 d; TBI-treated male BALB/c mice) reduces TBI-induced edema and neuroinflammation and reduces acute depression-like behavior.Methylene blue hydrate (2 mg/kg; i.v.; once, for 1 d; TBI-treated male BALB/c mice) reduces the percentage of inflammatory factor.Animal Model:Male NMRI mice
Dosage:50 and 100 mg/kg
Administration:Intraperitoneal injection; once, for 25 minutes
Result:Reduced the prepulse inhibition and reduced the increase in locomotor activity caused by phencyclidine (PCP).
Animal Model:CaMKIIα-tTA transactivator mice
Dosage:20 and 40 mg/kg
Administration:Oral administration; daily, for 6 months
Result:Inhibited Tau aggregation in CaMKIIα-tTA transactivator mice.
Animal Model:TBI-treated male BALB/c mice
Dosage:2 mg/kg
Administration:Intravenous injection; once, for 1 day
Result:Decreased the level of CD14, IL-1β, TNF-α, and CCL2 mRNA.
Animal Model:TBI-treated male BALB/c mice
Dosage:2 mg/kg
Administration:Intravenous injection; once, for 1 day
Result:Reduced the percentage of myeloid (CD11b+/GR1+) cells, reduced IL-1β and enhanced IL-10 expression in microglia.
体外研究：
Methylene blue (Basic Blue 9) hydrate (4.5 μM; BV2 microglia) alters the immune profile of LPS-activated BV2 microglia and decreased the level of CD14, IL-1β, TNF-α, and CCL2 mRNA.
Methylene blue (Basic Blue 9) hydrate is a guanylyl cyclase (sGC), monoamine oxidase A (MAO-A) and NO synthase (NOS) inhibitor. Methylene blue is a vasopressor and is often used as a dye in several medical procedures. Methylene blue hydrate through the nitric oxide syntase/guanylate cyclase signalling pathway to reduce prepulse inhibition. Methylene blue hydrate is a REDOX cycling compound and able to cross the blood-brain barrier. Methylene blue hydrate is a Tau aggregation inhibitor. Methylene blue hydrate reduces cerebral edema, attenuated microglial activation and reduced neuroinflammation.
体内研究：
Methylene blue (Basic Blue 9) hydrate (50 and 100 mg/kg; i.p.; once, for 25 min; male NMRI mice) reduces absent prepulse inhibition.Methylene blue hydrate (20 and 40 mg/kg; p.o.; daily, for 6 months; CaMKIIα-tTA transactivator mice) preserves cognition in mice expressing full-length pro-aggregant human Tau.Methylene blue hydrate (2 mg/kg; i.v.; once, for 1 d; TBI-treated male BALB/c mice) reduces TBI-induced edema and neuroinflammation and reduces acute depression-like behavior.Methylene blue hydrate (2 mg/kg; i.v.; once, for 1 d; TBI-treated male BALB/c mice) reduces the percentage of inflammatory factor.Animal Model:Male NMRI mice
Dosage:50 and 100 mg/kg
Administration:Intraperitoneal injection; once, for 25 minutes
Result:Reduced the prepulse inhibition and reduced the increase in locomotor activity caused by phencyclidine (PCP).
Animal Model:CaMKIIα-tTA transactivator mice
Dosage:20 and 40 mg/kg
Administration:Oral administration; daily, for 6 months
Result:Inhibited Tau aggregation in CaMKIIα-tTA transactivator mice.
Animal Model:TBI-treated male BALB/c mice
Dosage:2 mg/kg
Administration:Intravenous injection; once, for 1 day
Result:Decreased the level of CD14, IL-1β, TNF-α, and CCL2 mRNA.
Animal Model:TBI-treated male BALB/c mice
Dosage:2 mg/kg
Administration:Intravenous injection; once, for 1 day
Result:Reduced the percentage of myeloid (CD11b+/GR1+) cells, reduced IL-1β and enhanced IL-10 expression in microglia.
体外研究：
Methylene blue (Basic Blue 9) hydrate (4.5 μM; BV2 microglia) alters the immune profile of LPS-activated BV2 microglia and decreased the level of CD14, IL-1β, TNF-α, and CCL2 mRNA.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备